(Reuters) – Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.
The therapy, talquetamab-tgvs branded as Talvey, belongs to a class called bispecific antibodies designed to bring a cancer cell and an immune cell together so the body’s immune system can kill the cancer.
Talvey was approved as a weekly or biweekly subcutaneous, or under-the-skin, injection, the company said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
